A Randomised Open Controlled Parallel Group Study Comparing Norspan and Tramadol
CompletedPhase 4NCT00399178
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
To evaluate the efficacy and safety of Norspan versus Tiperol Retard among OA patients who are sub-optimally treated with current analgesic. Those patients may benefit from treatment with a long lasting analgesic.
Study details
- Official title
- A Randomised Open Controlled Parallel Group Multicenter Study to Evaluate the Efficacy and Safety of Norspan Versus Tiparol Retard in Subjects With Chronic Moderate to Severe OA Pain of the Hip and/or Knee.
- Conditions
- Interventions
- Drug: Transdermal delivery system
- Sponsor
- Mundipharma AB
- Start date
- 2006-11
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Sweden
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * OA diagnosis * BS11 greater than or equal to 4 at base line * Not adequately pain relieved with 4,000 mg paracetamol daily Exclusion Criteria: * Treated with high potent opioids for their OA pain * Treated with a regular dose for greater than one week of Tramadol, Codeine or dextropropoxifene during the last three months * Other chronic conditions requiring frequent analgesic therapy
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00399178